News | July 15, 2008

MIV Provides Study Update on Its Ultra-Thin Protea Stent Platform

July 17, 2008 - MIV Therapeutics Inc. today said its Protea ultra-thin cobalt-alloy bare metal stent has excelled in animal studies, reportedly showing the Protea is statistically superior to one of the best and most deliverable cobalt-alloy bare metal stents on the market.

The Protea is the company’s next generation bare metal stent with a strut thickness of 65 microns, a fixed geometry and uniform cell size for homogeneous delivery of drug to the local tissue, and a superior surface finish when compared to currently available cobalt alloy stents.

At one month following deployment, quantitative coronary angiography (QCA) showed percent diameter stenosis was significantly less for Protea (2±5 percent vs. 17±16 percent, p=0.032). By histomorphometry, intima thickness (0.11±0.05 mm vs. 0.23±0.11 mm, p=0.003) and percent area stenosis (19±1 vs. 32±11 percent, respectively, p=0.004) were also significantly lower for Protea. The strut injury score was low and similar between the two groups. QCA percent stenosis; intima thickness; and percent area stenosis of overlapping Protea stents were 3±3 percent, 0.13±0.02 mm, and 22±4 percent, respectively. Stable fibrocellular neointimal incorporation of all stents including overlapped Protea, with complete endothelialization and minimal inflammation, was seen at one month.

The Protea is used as the bare metal stent platform for the VESTAsync drug eluting stent in the VESTASYNC II trial. The company said in addition to a superior surface finish due to a proprietary finishing technique and thinner struts, the surface area of the Protea was designed to be the same as that of the GenX, which allows the company to use the same dose and drug delivery system for both stents.

For more information:

Related Content

Videos | Stents | September 11, 2018
This is an animation showing how the dedicated bifurcation stent developed by Advanced Bifurcation Systems (ABS) is d
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents | January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents | January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents | November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin
Overlay Init